Mercer College of Pharmacy's CCORE will have a booth at the December 2018 ASHP Midyear Clinical Meeting and Exhibition. Please register for a meeting time through the Personnel Placement Service.
Fellows will divide their time between the College and Galt or Arbor, where they will help advance the clinical development of secondary indications of approved drugs and support scientific affairs of Galt or Arbor products as they move from development to commercialization. The College of Pharmacy’s Center for Clinical Outcomes Research and Education, or CCORE, will support and guide fellows assigned research projects in medical affairs or outcomes. Fellows will publish their research findings in peer-reviewed publications and present at scientific conferences, in addition to supporting the Mercer University Doctor of Pharmacy (Pharm.D.) didactic program.
These fellowships will give a graduate in-depth experience in medical affairs and/or outcomes research. New pharmacists and pharmaceutical scientists will have valuable expertise as they transition into the workforce.
Applications from candidates with a Pharm.D. degree or a graduate degree in outcomes research are sought for the July 2019 - June 2020 cycle. Candidates should send their curriculum vitae with two references listed and a cover letter by Feb. 1, 2019, to Dr. Peasah at email@example.com. Qualified candidates will be contacted for interviews in March.
The Mercer University College of Pharmacy’s Center for Clinical Outcomes Research and Education (CCORE) develops quantitative models for health care outcomes, public health, pharmacoeconomics, and comparative effectiveness related to medications, devices or health care. CCORE serves as a resource for other universities, industries and agencies and is made up of faculty members with diverse backgrounds in health services research, health outcomes research, survey and focus group facilitation, clinical research and statistical analysis using SAS, STATA and SPSS software. The center has completed data management for a Bill Gates Foundation grant project, data analysis of a diabetic project for a medical device company, Valeritas, and consults with the Georgia Tobacco Use Prevention Program on an economic evaluation of the program. CCORE is led by Samuel Peasah, Ph.D., MBA, RPh.
Arbor Pharmaceuticals is a specialty pharmaceutical company that markets over 20 FDA-approved products in multiple therapeutic areas, including cardiovascular, neuroscience, pediatric, endocrinology and hospital markets. Arbor was acquired by Mercer alumnus Ed Schutter, BSPHARM ‘77, MBA, and two other investors in 2010. Since acquisition, the company has grown from less than $2 million in annual sales to more than $300 million. The company is led by a management team with extensive pharmaceutical industry experience in clinical development, medical and regulatory affairs, manufacturing, quality control and commercialization.
The company currently employs numerous MDs, PhDs, PharmDs, nurses and other scientists who work in medical, clinical or regulatory affairs, manufacturing, quality control, managed markets and commercial operations. Fellows will work primarily within our medical department, led by Evan Scullin, M.D., along with Mercer alumna Rebecca Neal Burns, PHARM ’12, PHD ’12. Fellows will likely be involved in projects ranging from pharmacoeconomic analysis of products, drug safety investigations and research of new development or in-licensing opportunities. For more information regarding Arbor Pharmaceuticals or any of its products, please visit www.arborpharma.com.
Galt Pharmaceuticals is a specialty pharmaceutical company with a unique operational platform that seeks to serve unmet needs within health care. The company applies superior pharmaceutical, managed care and marketing expertise to develop, license and acquire niche pharmaceutical products for distribution through unique channels consisting of an extensive niche independent pharmacy network. For more information, please visit www.galtrx.com.
Fellows will work alongside Galt co-founder Barry Patel, PHARMD ‘92. Dr. Patel co-founded his own pharmaceutical outcomes research and education company, Total Therapeutic Management (TTM), along with another Mercer graduate in 1995, and successfully sold the company to Indegene Lifesystems in 2013. His latest venture, Galt Pharmaceuticals, is co-founded with fellow Mercer graduate, William Smith, PHARMD ‘88, to further develop approved drugs for unmet health care needs, while commercializing them for current needs through a unique distribution model that relies exclusively on independent pharmacies.